Bendroflumethiazide may increase the hypotensive activities of Candesartan. The serum concentration of Azithromycin can be decreased when it is combined with Enzalutamide. The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Canertinib. The metabolism of Chlorphenamine can be decreased when combined with Isradipine. Tadalafil may increase the antihypertensive activities of Zofenopril. The risk or severity of adverse effects can be increased when Levocabastine is combined with Citalopram. The risk or severity of adverse effects can be increased when Diflunisal is combined with Meclofenamic acid. The serum concentration of Flurandrenolide can be decreased when it is combined with Rifabutin. The risk or severity of adverse effects can be increased when Methaqualone is combined with Brompheniramine. Cyclobenzaprine may increase the serotonergic activities of Pargyline. The serum concentration of Bupivacaine can be increased when it is combined with Nadolol. The metabolism of Betaxolol can be decreased when combined with Celecoxib. Vinpocetine may increase the hypotensive activities of Cyclopenthiazide. The metabolism of Chlorphenamine can be decreased when combined with Manidipine. The metabolism of Irbesartan can be increased when combined with Rifampicin. Lofexidine may increase the hypotensive activities of Xylometazoline. The risk or severity of adverse effects can be increased when Lisofylline is combined with Methylprednisolone. The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Flurandrenolide. The metabolism of Mianserin can be decreased when combined with Cimetidine. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Miconazole resulting in a loss in efficacy. Diclofenac may decrease the antihypertensive activities of Propranolol. Benzphetamine may increase the analgesic activities of Fentanyl. The risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone. The metabolism of Ethylmorphine can be decreased when combined with Lovastatin. The risk or severity of adverse effects can be increased when Prednisolone is combined with Huperzine A. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Empagliflozin. The metabolism of Lercanidipine can be decreased when combined with Atomoxetine. Mefloquine may increase the QTc-prolonging activities of Gemifloxacin. Tranilast may decrease the antihypertensive activities of Pindolol. The serum concentration of Colchicine can be increased when it is combined with Testosterone. Isoxicam may increase the nephrotoxic activities of Tacrolimus. The therapeutic efficacy of Indapamide can be decreased when used in combination with Isoxicam. The serum concentration of Tolvaptan can be increased when it is combined with Azithromycin. Salicylamide may increase the anticoagulant activities of Darexaban. The risk or severity of adverse effects can be increased when Acemetacin is combined with Desonide. Tinoridine may increase the nephrotoxic activities of Cyclosporine. The metabolism of Clotiazepam can be decreased when combined with Efavirenz. The risk or severity of adverse effects can be increased when Mecamylamine is combined with Moexipril. Naproxen may increase the neuroexcitatory activities of Sparfloxacin. Azelastine may increase the antiplatelet activities of Naftopidil. The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide. The metabolism of Rifabutin can be decreased when combined with Cobicistat. Amobarbital may increase the hypotensive activities of Dapagliflozin. Trimethoprim may increase the QTc-prolonging activities of Erythromycin. Salsalate may decrease the antihypertensive activities of Aliskiren. The serum concentration of Zidovudine can be decreased when it is combined with Chymostatin. Promethazine may increase the QTc-prolonging activities of Ofloxacin. The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Atamestane. The risk or severity of adverse effects can be increased when Naproxen is combined with Mometasone. The risk or severity of adverse effects can be increased when Probenecid is combined with Pegloticase. Salicylic acid may increase the anticoagulant activities of Becaplermin. The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Vorinostat. The risk or severity of adverse effects can be increased when Rufinamide is combined with Meclizine. The serum concentration of Everolimus can be increased when it is combined with Enalapril. The serum concentration of Tizanidine can be increased when it is combined with Azithromycin. The risk or severity of adverse effects can be increased when Methaqualone is combined with Amitriptyline. The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Josamycin. The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil. Epoprostenol may increase the hypotensive activities of Cyclopenthiazide. The bioavailability of Paramethasone can be decreased when combined with Magnesium Hydroxide. Cyclopenthiazide may increase the hypercalcemic activities of Ergocalciferol. The risk or severity of adverse effects can be increased when Fluphenazine is combined with Scopolamine. The metabolism of Busulfan can be decreased when combined with Clemastine. The therapeutic efficacy of Voglibose can be decreased when used in combination with Levonorgestrel. The risk or severity of adverse effects can be increased when PTC299 is combined with Fluprednidene. The serum concentration of Avanafil can be increased when it is combined with Atazanavir. The risk or severity of adverse effects can be increased when Candesartan is combined with Pirfenidone. The serum concentration of Simvastatin can be decreased when it is combined with Peginterferon alfa-2b. The risk or severity of adverse effects can be increased when Desflurane is combined with Betaxolol. Isoprenaline may increase the hypokalemic activities of Etacrynic acid. The serum concentration of Eliglustat can be increased when it is combined with Dihydroergotamine. The risk or severity of adverse effects can be increased when Eprosartan is combined with Indomethacin. Phenformin may increase the hypoglycemic activities of Tolbutamide. The risk or severity of adverse effects can be increased when Reserpine is combined with Spironolactone. The serum concentration of Cobicistat can be increased when it is combined with Itraconazole. Cyclosporine may increase the neuromuscular blocking activities of Neosaxitoxin. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol. The serum concentration of Levonorgestrel can be increased when it is combined with Voriconazole. The bioavailability of Deflazacort can be decreased when combined with Magnesium Hydroxide. The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Gatifloxacin. Prulifloxacin may increase the hypoglycemic activities of Empagliflozin. The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Estrone. The risk or severity of adverse effects can be increased when Bufexamac is combined with Desonide. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Nadolol. The metabolism of Clonidine can be decreased when combined with Citalopram. The metabolism of Arachidonic Acid can be decreased when combined with Cyclosporine. The metabolism of Quinidine can be decreased when combined with Topiroxostat. The risk or severity of adverse effects can be increased when Irbesartan is combined with Zofenopril. Perindopril may increase the hypotensive activities of Metyrosine. The risk or severity of adverse effects can be increased when Dexamethasone is combined with Hepatitis B Vaccine (Recombinant). Pentobarbital may increase the hypotensive activities of Nadolol. The metabolism of Tamsulosin can be increased when combined with Fosphenytoin. The metabolism of Indomethacin can be decreased when combined with Zucapsaicin. The risk or severity of adverse effects can be increased when Rescinnamine is combined with Aceclofenac. The metabolism of Methaqualone can be decreased when combined with Clotrimazole. The risk or severity of adverse effects can be increased when Etidocaine is combined with Iloperidone. The risk or severity of adverse effects can be increased when Clomipramine is combined with Hydroflumethiazide. The metabolism of Aminophenazone can be decreased when combined with Dronedarone. The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Bufexamac. The serum concentration of Plazomicin can be decreased when it is combined with Nafcillin. The risk or severity of adverse effects can be increased when Resveratrol is combined with Rimexolone. The risk or severity of adverse effects can be increased when Butalbital is combined with Clemastine. Bromfenac may decrease the excretion rate of Tobramycin which could result in a higher serum level. The risk or severity of adverse effects can be increased when Lorazepam is combined with Etoperidone. The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Seratrodast. The risk or severity of adverse effects can be increased when Budesonide is combined with Tecemotide. The risk or severity of adverse effects can be increased when Zomepirac is combined with Rimexolone. The risk or severity of adverse effects can be increased when Dapsone is combined with Mafenide. The risk or severity of adverse effects can be increased when Metolazone is combined with Nebivolol. The metabolism of Gavestinel can be decreased when combined with Losartan. The risk or severity of adverse effects can be increased when Trandolapril is combined with Isosorbide Mononitrate. The risk or severity of adverse effects can be increased when Ergotamine is combined with Doxorubicin. The metabolism of Dasabuvir can be decreased when combined with Betaxolol. The therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Hydroxyprogesterone caproate. The serum concentration of Edoxaban can be increased when it is combined with Telmisartan. Iloprost may increase the hypotensive activities of Moexipril. Secobarbital may increase the hypotensive activities of Metipranolol. Iproclozide may increase the hypotensive activities of Xylometazoline. The metabolism of Efavirenz can be decreased when combined with Rucaparib. The risk or severity of adverse effects can be increased when Saxagliptin is combined with Cilazapril. The risk or severity of adverse effects can be increased when Oxaprozin is combined with Bufexamac. Terazosin may decrease the vasoconstricting activities of Formoterol. The serum concentration of Streptomycin can be decreased when it is combined with Meticillin. The risk or severity of adverse effects can be increased when Salicylic acid is combined with Carbaspirin calcium. The serum concentration of Amiodarone can be increased when it is combined with Ritonavir. The risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid. The serum concentration of Tacrolimus can be increased when it is combined with Erythromycin. Venlafaxine may increase the tachycardic activities of Orciprenaline. The risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam. The risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.